decreased by 13.1%. 2. FINANCIAL POSITION The Consolidated Balance Sheet as of 31 March 2019 is summarized as follows. Assets As at 31 March 2019, the Company’s total Assets was Baht 22,809.6 million

its revenue streams which mitigate the risk of reliance on sales in China. At present, the Company’s products are well - received in the Philippines but still could not make up for the slowdown in sales

Assets 240.87 305.00 -64.13 -21.03 Non-Current Assets 260.05 259.75 0.30 0.12 Total Assets 500.92 564.75 -63.83 -11.30 Current Liabilities 182.60 202.31 -19.71 -9.74 Non-Current Liabilities 146.89 156.49

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

The Consolidated Balance Sheet as of 30 September 2018 is summarized as follows. Assets As at 30 September 2018, the Company’s total Assets was Baht 23,137.0 million, increased by Baht 1,758.8 million

Limited Management Discussion and Analysis for the Quarter Ended on September 30, 2018 7 Financial Position As at September 30, 2018, the Company and its subsidiaries had total assets amounted to Baht

Position as at September 30 , 2018 and December 31, 2017 (Unit : Million Baht) 2018 2017 Inc./(Dec.) % Current Assets 451.49 305.00 146.49 48.03 Non-Current Assets 1,013.18 259.75 753.43 290.06 Total Assets

out of 16.47 MW. However, the company had an “all risk” insurance which covers all risks on the company’s Solar energy units. In fact, the company already received claims of damaged assets in Q3/2018

customer base and diversify its revenue streams which mitigate the risk of reliance on sales in China. At present, the Company’s products are well - received in the Philippines but still could not make up

until the situation is well. Moreover, in order to reduce the effect on the shareholders from the postponement of the 2020 Annual General Meeting, the Board of Directors Meeting on April 9, 2020 had a